StockNews.AI
VALN
StockNews.AI
14 hrs

Johnson Fistel Investigates Valneva Following FDA Suspension

1. Valneva faces investigation for potential securities law violations. 2. FDA suspended Valneva's chikungunya vaccine license due to adverse reports. 3. Investors may be eligible for recovery of losses from class action. 4. Johnson Fistel represents investors in shareholder derivative lawsuits. 5. Past results indicate strong performance for recovery efforts.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The suspension of the vaccine license negatively impacts Valneva's revenue potential and investor confidence. Historical cases show similar downsides for biopharma companies facing FDA sanctions.

How important is it?

The article directly connects to Valneva's securities issues and FDA actions. Loss recovery class actions indicate severe investor concerns.

Why Short Term?

Immediate FDA actions and investigations could lead to quick price drops. Similar incidents have historically hit stock prices rapidly.

Related Companies

JNJMRNANVAX
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Valneva SE (NASDAQ: VALN) regarding possible violations of federal securities laws. Investors who purchased Valneva securities may be eligible to recover losses stemming from alleged misrepresentations and omissions made by the company and its executives. What if I purchased Valneva securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your losses, follow the link provided: https://www.johnsonfistel.com/investigations/valneva-se/ For more information, contact James Baker at (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com. Background: On August 25, 2025, Valneva acknowledged that the FDA had, with immediate effect, suspended the license for its chikungunya vaccine Ixchiq following four reports of serious adverse events consistent with the disease, thereby mandating that Valneva cease all shipping and sale of the vaccine within the United States. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights:   Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs’ securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. Contact: Johnson Fistel, PLLP 501 W. Broadway, Suite 800, San Diego, CA 92101 James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471 jimb@johnsonfistel.com or fjohnson@johnsonfistel.com 

Related News